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Oxidative Stress, T Cell DNA Methylation, and Lupus
YePeng Li, Gabriela Gorelik, Faith M. Strickland, and Bruce C. Richardson
Objective. Lupus develops when genetically pre-
disposed people encounter environmental agents, such
as ultraviolet light, silica, infections, and cigarette
smoke, that cause oxidative stress, but how oxidative
damage modifies the immune system to cause lupus
flares is unknown. We previously showed that inhibiting
DNA methylation in CD4 T cells by blocking ERK
pathway signaling is sufficient to alter gene expression,
and that the modified cells cause lupus-like autoimmu-
nity in mice. We also reported that T cells from patients
with active lupus have decreased ERK pathway signal-
ing, have decreased DNA methylation, and overexpress
genes normally suppressed by DNA methylation. This
study was undertaken to test whether oxidizing agents
decrease ERK pathway signaling in T cells, decrease
DNA methyltransferase levels, and cause demethylation
and overexpression of T cell genes similar to that found
in T cells from patients with active lupus.
Methods. CD4 T cells were treated with the
oxidizers H2O2 or ONOO
. Effects on ERK pathway
signaling were measured by immunoblotting, DNA
methyltransferase 1 (DNMT-1) levels were measured by
reverse transcriptase–polymerase chain reaction (RT-
PCR), and the methylation and expression of T cell
genes were measured using flow cytometry, RT-PCR,
and bisulfite sequencing.
Results. H2O2 and ONOO
 inhibited ERK path-
way signaling in T cells by inhibiting the upstream
regulator protein kinase C, decreased DNMT-1 levels,
and caused demethylation and overexpression of genes
previously shown to be suppressed by DNA methylation
in T cells from patients with active lupus.
Conclusion. Our findings indicate that oxidative
stress may contribute to human lupus flares by inhibit-
ing ERK pathway signaling in T cells to decrease
DNMT-1 and cause DNA demethylation.
Lupus remains a poorly understood disease caus-
ing disability and early mortality in those affected.
Familial clustering and the identification of genetic
susceptibility loci indicate that genes contribute to lupus
(1), but incomplete concordance in identical twins (2)
and reports that drugs like procainamide and hydral-
azine cause a lupus-like disease in genetically predis-
posed people (3) indicate that an environmental com-
ponent is also required. Commonly encountered
environmental agents, such as ultraviolet (UV) light,
cigarette smoke, and silica, and physiologic stressors like
infections are also associated with lupus flares (4–6), but
how these agents might trigger lupus flares is unclear.
However, UV light, smoking, silica, infections, and other
stressors stimulate reactive oxygen species production
(7), suggesting that oxidative damage to proteins or
other molecules may contribute to lupus flares.
Studies from several groups demonstrate that
human lupus flares are characterized by oxidative dam-
age to serum proteins and other molecules. The protein
modifications include nitration, caused by superoxide
(O2
) combining with nitric oxide (NO) to form per-
oxynitrite (ONOO) (8,9), as well as increased levels of
protein carbonyls, decreased protein thiol levels, and
others (10,11). Lupus T cells in particular are subjected
to oxidative stress. T cells from patients with active lupus
have increased mitochondrial oxidative phosphoryla-
tion, resulting in O2
 generation that modifies proteins,
either directly by oxidation or indirectly by combining
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with intracellular NO (10). How T cell protein oxidation
might contribute to lupus flares, though, is unclear.
Work from our group demonstrates that exoge-
nous agents that inhibit DNA methylation can contrib-
ute to the development of lupus-like autoimmunity by
modifying CD4 T cell chromatin structure and gene
expression. We reported that procainamide and hydral-
azine are DNA methylation inhibitors (12), and that
treating normal CD4 T cells with the DNA methyl-
transferase inhibitor 5-azacytidine, or procainamide or
hydralazine, inhibits methylation of genes including
ITGAL (CD11a) and TNFSF7 (CD70), increasing their
expression and changing the T cells from antigen-
specific “helper” cells into autoreactive cells (3). We also
reported that T cells modified with these and other
DNA methylation inhibitors are sufficient to cause lupus
in animal models (3). Importantly, the same changes in
T cell DNA methylation, gene expression, and cellular
function are found in CD4 T cells from patients with
active lupus (3,7).
Impaired ERK pathway signaling in T cells con-
tributes to the epigenetic changes. The signaling impair-
ment causes a failure to up-regulate DNA methyltrans-
ferase 1 (DNMT-1) during mitosis, so DNA methylation
patterns are not completely copied from the parent to
the daughter cells, causing demethylation and overex-
pression of genes that contribute to lupus flares (3).
Evidence that CD4 T cells treated with the ERK
pathway inhibitors hydralazine or U0126 have hypom-
ethylated DNA and are sufficient to cause lupus in
murine models (13), and that transgenic mice with an
inducible T cell–specific ERK pathway defect similarly
develop demethylated T cell DNA and lupus-like auto-
immunity (14,15) demonstrates that impaired ERK
pathway signaling in T cells is sufficient to cause lupus-
like autoimmunity. More recent studies demonstrate
that the ERK pathway defect in lupus T cells is due to
protein kinase C (PKC) nitration and that hydralazine
also inhibits PKC (16,17).
Since UV light, infections, silica, and smoking
stimulate oxidative stress (7), and increased mitochon-
drial oxidative phosphorylation generates reactive oxy-
gen species like O2
 and ONOO in T cells from
patients with active lupus (8–11), we hypothesized that
reactive oxygen species generated from environmental
exposures and/or increased mitochondrial activity may
inhibit ERK pathway signaling in T cells, thereby de-
creasing DNMT-1 expression to cause demethylation
and overexpression of genes that contribute to lupus
flares. We therefore treated normal human CD4 T
cells with H2O2 or ONOO
 and tested whether these
oxidizers inhibit ERK pathway signaling and cause de-
methylation and overexpression of methylation-sensitive
genes, similar to the signaling and epigenetic changes
found in lupus T cells.
MATERIALS AND METHODS
Subjects. Healthy men and women without chronic
inflammatory diseases or other significant illnesses who were
younger than 60 years of age (mean  SD age 38  16 years;
n  15) were recruited by advertising. These studies were
approved by the University of Michigan Institutional Review
Board.
Chemicals and reagents. H2O2, hydralazine, and
N-acetylcysteine (NAC) were purchased from Sigma-Aldrich,
and ONOO was purchased from Calbiochem.
T cell isolation and culture. Peripheral blood mono-
nuclear cells (PBMCs) were isolated by density-gradient cen-
trifugation and then cultured in complete tissue culture me-
dium (RPMI 1640/10% fetal bovine serum) and stimulated for
18–24 hours with 1 g/ml of phytohemagglutinin (PHA;
Murex) as previously described (18). The cells were then
washed 3 times with phosphate buffered saline (PBS) and
cultured alone or with 50 M H2O2, 50 M ONOO
, 10 M
hydralazine, and/or 1 mM NAC for another 72 hours. CD4
cells were then isolated by negative selection using magnetic
beads (CD4 T cell isolation kit; Miltenyi Biotec), according
to the manufacturer’s instructions, and used immediately.
Flow cytometry. Cy5-conjugated anti-CD3, fluorescein
isothiocyanate (FITC)–conjugated anti-CD8, Cy5-conjugated
anti-CD8, Cy5-conjugated anti-CD4, phycoerythrin (PE)–
conjugated anti-CD158b (killer cell immunoglobulin-like re-
ceptor 2DS2 [KIR-2DS2]), PE-conjugated anti-NKB1 (KIR-
3DL1), and FITC-conjugated anti-CD28 were obtained from
BD PharMingen. PE-conjugated anti-CD158d (KIR-2DL4)
was obtained from R&D Systems and PE-conjugated anti-
CD158a/h (KIR-2DL1/2DS2) and PE-conjugated anti-
CD158b1/b2 (KIR-2DL2/2DL3/2DS2) were obtained from
Beckman Coulter Immunotech. Five microliters of each PE-
conjugated anti-KIR antibody was mixed to form a cocktail
and used to stain the cells (19). All labeling procedures were
performed on ice in PBS containing 10% horse serum and
normal human AB serum (Invitrogen) and sodium azide. Cell
staining was performed as previously described (20), and the
stained cells were analyzed using a FACSCalibur flow cytom-
eter (BD Biosciences).
Reverse transcriptase–polymerase chain reaction (RT-
PCR). Total RNA was isolated using the RNeasy Mini kit
(Qiagen). KIR-2DL4, CD70, DNMT-1, and -actin transcripts
were measured in bead-purified T cells using a Rotor-Gene
3000 (Corbett Robotics) and the QuantiTect SYBR Green
RT-PCR kit (Qiagen) according to the manufacturer’s instruc-
tions. CD70, DNMT-1, and -actin primers and amplification
protocols have been described previously (20–22). Primers
designed to match polymorphic positions unique to KIR-2DL4
genes have been described previously (20,23).
ERK pathway immunoblot assays. Purified CD4 T
cells were suspended in RPMI 1640 supplemented with 10%
fetal calf serum, 2 mM glutamine and penicillin/streptomycin
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and then left unstimulated or stimulated with 50 ng/ml phorbol
myristate acetate (PMA) for 15 minutes at 37°C. Where
indicated, cells were incubated in the presence or absence of
hydralazine (10 M), H2O2 (50 M), or ONOO
 (50 M) for
60 minutes before PMA stimulation. Following stimulation,
the cells were lysed, then total and phosphorylated ERK,
MEK, RAF, and PKC were measured by immunoblotting as
described (16). The following primary antibodies were used at
a 1:1,000 dilution: anti–phospho-Raf (Ser338), anti–phospho–
MEK-1/2 (Ser217/221), anti–MEK-1/2, and anti–phospho-PKC
(T505) (Cell Signaling Technology). Polyclonal rabbit anti-
active MAPK (1:5,000) was purchased from Promega. Second-
ary antibodies included anti-rabbit IgG horseradish peroxidase
(HRP; 1:2,000) (Cell Signaling Technology) and anti-mouse
IgG HRP (1:4,000; Sigma-Aldrich).
Pyrosequencing. Genomic DNA was isolated from T
cells using the DNeasy Blood and Tissue kit (Qiagen) and then
bisulfite treated using the EZ DNA Methylation-Gold kit
(Zymo Research). CD70 and KIR-2DL4 promoter methyl-
ation were determined by Pyrosequencing as described previ-
ously (20).
Statistical analysis. Statistical analyses were per-
formed using Student’s t-test or analysis of variance (ANOVA)
(24) in Systat software.
RESULTS
Increased methylation-sensitive T cell gene ex-
pression after treatment with H2O2 or ONOO
. CD4
T cell TNFSF7 (CD70) and KIR genes are silenced
primarily by DNA methylation, and inhibiting the repli-
cation of DNA methylation patterns during mitosis is
sufficient to demethylate their respective regulatory
regions and induce gene expression (20,22). These genes
are also aberrantly demethylated and expressed on
CD4 T cells from patients with active lupus (25). Initial
experiments were conducted to test whether oxidizing
agents induce the expression of these genes. We selected
H2O2 because this oxidizer is generated by mitochon-
drial oxidative phosphorylation and superoxide dismu-
tase in metabolically active T cells such as those de-
scribed in lupus flares (8), and ONOO because this
oxidizer contributes to protein nitration in lupus (10).
PBMCs from healthy individuals were stimulated
for 18 hours with PHA and treated with the indicated
concentrations of ONOO or H2O2 for 72 hours. CD4
T cell CD70 and KIR expression were then measured by
flow cytometry and RT-PCR using protocols similar to
those previously used to activate these and other epige-
netically silenced T cell genes with DNMT inhibitors
such as 5-azacytidine (18,20,22). As shown in Figure 1A,
normal CD4 T cells did not express KIR proteins, and
ONOO caused a dose-dependent increase in the num-
ber of KIR-expressing CD4 T cells. Figure 1B similarly
shows that relatively few CD4 T cells normally express
CD70, and that ONOO increased the percentage of
CD4CD70 T cells, similar to its effects on KIR.
Figure 1. Effects of oxidative stress on killer cell immunoglobulin-like
receptor (KIR) and CD70 gene expression in T cells. A–D, Peripheral
blood mononuclear cells (PBMCs) from 3 healthy young donors were
stimulated with phytohemagglutinin (PHA), treated with ONOO (A
and B) or H2O2 (C and D), and then stained with fluorochrome-
conjugated antibodies to CD4, CD8, and KIR proteins (A and C) or
fluorochrome-conjugated anti-CD70 (B and D) and analyzed by flow
cytometry. Values are the mean  SEM of 3 determinations. P values
were determined by analysis of variance. E and F, PBMCs from 4
healthy young donors were stimulated with PHA and then treated with
the indicated concentrations of hydralazine (Hyd), H2O2, or ONOO

as in A–D. CD4 cells were then purified and KIR-2DL4 (E) or CD70
(F) transcripts were measured by reverse transcriptase–polymerase
chain reaction. Results are presented relative to untreated T cells. Bars
show the mean  SEM. Values above the bars are P versus control, by
t-test. G–J, PBMCs from healthy young donors were stimulated and
then cultured alone (control) or with 1 mM N-acetylcysteine (NAC),
50 M H2O2, 50 M ONOO
, 1 mM NAC plus 50 M H2O2, or 1 mM
NAC plus 50 M ONOO. The cells were then stained for CD4 and
KIR (G and I) or CD4 and CD70 (H and J) and analyzed as above.
Bars show the mean SEM from 3 independent experiments in G and
I and from 5 independent experiments in H and J. P values are versus
H2O2 in G and H and versus ONOO
 in I and J.
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H2O2 also increased the percentages of CD4KIR T
cells (Figure 1C) and CD4CD70 T cells (Figure 1D).
The effects of H2O2 and ONOO
 on CD4 T
cell KIR and CD70 gene expression were confirmed at
the messenger RNA (mRNA) level. The KIR gene locus
contains 14 closely related genes, and most people
inherit a different repertoire of KIR genes. Everyone,
however, has KIR2DL4 (26). CD4 T cells from healthy
volunteers were stimulated with PHA and treated with
50 M H2O2 or 50 M ONOO
, and 72 hours later
KIR2DL4 and CD70 mRNA were measured by RT-
PCR, and the results were expressed relative to -actin.
Hydralazine (10 M), which inhibits DNA methylation
by blocking ERK pathway signaling through its effects
on PKC (16), was included as a control. All 3 agents
increased KIR mRNA levels (Figure 1E) and CD70
mRNA levels (Figure 1F), consistent with our previous
findings with other DNA methylation inhibitors (19,22).
We next tested whether the antioxidant NAC
inhibited the effects of H2O2 and ONOO
 on CD4 T
cell gene expression. NAC is a thiol-containing antioxi-
dant that combines rapidly with reactive oxygen species
(27), does not inhibit T cell proliferation (28), and has
been reported to decrease oxidative stress and flare
severity in lupus patients (29). As shown in Figure 1G, 1
mM NAC had no effect on T cell KIR expression, while
H2O2 increased KIR expression, and NAC prevented
the effect of H2O2 on KIR expression (P  0.03, H2O2
alone versus H2O2 and NAC). The combination of H2O2
and NAC also inhibited the effect of H2O2 on T cell
CD70 expression (P  0.04) (Figure 1H). Similarly,
Figure 1I shows that NAC inhibited the effect of
ONOO on CD4 KIR expression (P  0.02), and
Figure 1J shows the same inhibitory effect on CD70
expression induced by ONOO (P  0.03). These
results demonstrate that the effects of these oxidizing
agents on CD4 T cell gene expression can be pre-
vented with a clinically tested and safe antioxidant.
Controls included comparing the effects of
ONOO, H2O2, and hydralazine on CD4CD28 and
CD4CD28 T cells. CD28 T cells are a “senescent”
subset with shortened telomeres and decreased replica-
tive potential. This subset is present in small numbers in
younger (60 years of age) healthy people, but increases
with further aging. The subset develops earlier in pa-
tients with chronic inflammatory diseases like rheuma-
toid arthritis and also with chronic stimulation in vitro,
likely due to replicative stress (30). Importantly, this
subset overexpresses a repertoire of methylation-
sensitive genes similar to those overexpressed by exper-
imentally demethylated T cells (21,31). We used flow
cytometry to compare the effects of ONOO, H2O2, and
hydralazine on KIR and CD70 expression by this subset
in the same subjects. Hydralazine, H2O2, and ONOO

all increased KIR expression on the CD4CD28 and
CD4CD28 subsets (P  0.05 for all 3 treatments
versus untreated controls) (data available from the
author upon request). However, while hydralazine,
H2O2, and ONOO
 increased CD70 expression on the
CD4CD28 subset, the effect of this oxidizer on
CD70 expression by the CD4CD28 subset was much
smaller, and was of borderline significance only for
H2O2 (P  0.048). In all cases except hydralazine, the
increase was somewhat greater on the CD28 subset
than on the CD28 subset (P  0.05). However, since
the CD4CD28 subset represents a small subset
within the total CD4 population (mean  SD 6.3 
2.2% in this cohort), we used unfractionated CD4 cells
in further experiments.
Inhibition of T cell DNA methylation by H2O2
and ONOO. Since the CD70 and KIR genes are
suppressed by DNA methylation in CD4 T cells, we
hypothesized thatH2O2 andONOO
may inhibitmethyl-
ation of the same regulatory regions in or near the
TNFSF7 (CD70) and KIR2DL4 genes previously identi-
fied by our group in CD4 lupus T cells, as well as in
CD4 T cells treated with other DNA methylation
inhibitors (20,22). PBMCs from healthy subjects were
stimulated with PHA and treated with 50 M H2O2 or
50 M ONOO, and 72 hours later CD4 T cells were
isolated and methylation of their regulatory regions was
measured by Pyrosequencing.
Figure 2A shows the effects of H2O2 and
ONOO onKIR2DL4methylation relative to themethyl-
ation of the same CG pair in untreated T cells (P 
0.001; n  4 experiments), and Figure 2B shows their
effects on the methylation of TNFSF7, also relative to
untreated T cells (P  0.001; n  3 experiments). Both
oxidizing agents caused a significant decrease in the
methylation of the same sequences previously shown to
suppress transcription when methylated in vitro (20,22).
Importantly, the same sequences demethylate in CD4
T cells from patients with active lupus but not those with
inactive lupus (19,20,22).
Controls included comparing the methylation
status of 3 CG pairs located 440, 428, and 389 bp
5 of the TNFSF7 transcription start site. CD4 T cells
from 4 healthy donors were left untreated or treated
with H2O2 or ONOO
, and methylation of the same
sequences was compared using bisulfite sequencing. We
previously demonstrated that these 3 CG pairs remain
methylated in CD4 T cells treated with the DNMT
inhibitors 5-azacytidine and procainamide, with the
MEK inhibitors PD98059 and U0126, and with the
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PKC inhibitor hydralazine (22). H2O2 and ONOO

had no significant effect on the methylation of these CG
pairs (data are available online at http://sitemaker.
umich.edu/brlab/home).
T cell DNA methylation patterns are replicated
during mitosis primarily by DNMT-1. We tested whether
H2O2 and ONOO
 decrease CD4 T cell DNMT-1
levels. PBMCs from 4 healthy subjects were stimulated
with PHA for 18 hours and then cultured alone or with
50 M H2O2 or 50 M ONOO
 as described in the
Figure 1 legend. Twenty-four hours later, CD4 cells
were purified, RNA was isolated, DNMT-1 transcripts
were measured by RT-PCR, and the results were ex-
pressed relative to -actin. Hydralazine (10 M), which
inhibits T cell DNA methylation by decreasing DNMT-1
levels through inhibitory effects on PKC activation and
ERK pathway signaling (16), was included as a positive
control. Figure 3 shows that all 3 agents caused a similar
decrease in DNMT-1 levels.
Since both H2O2 and ONOO
 decreased
DNMT-1 levels, we next determined if H2O2 and
ONOO also inhibited ERK pathway signaling, similar
to hydralazine and the defect in lupus T cells (16).
PBMCs from healthy young controls were stimulated
with PHA for 18 hours, and then CD4 T cells were
isolated, treated with 50 M H2O2, 50 M ONOO
, or
10 M hydralazine for 60 minutes, and then restimulated
with PMA (32). Fifteen minutes later the cells were
lysed, and cytoplasmic proteins were then fractionated
by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis, transferred onto nitrocellulose membranes,
and serially probed with antibodies to the active dually
phosphorylated forms of ERK-1/2, phospho–MEK-1/2
Ser217/221, and Raf-1 p-Ser338. -actin was used as a
loading control. Figure 4A shows representative immuno-
blots of phospho-Raf, phospho-MEK, phospho-ERK,
and actin in PMA-stimulated T cells that were left
untreated or treated with hydralazine, H2O2, or
ONOO. Figure 4B shows the mean  SEM of the
Figure 3. DNMT-1 mRNA levels in CD4 T cells treated with H2O2
or ONOO. Peripheral blood mononuclear cells from 4 young donors
were stimulated and cultured alone or with 10 M hydralazine (Hyd),
50 M H2O2, or 50 M ONOO
 as described in the Figure 1 legend.
CD4 cells were isolated 24 hours later, and RNA was isolated and
DNMT-1 transcripts were measured relative to -actin. Bars show the
mean  SEM. P values are versus control.
Figure 2. H2O2 and ONOO
 inhibit T cell DNA methylation. Periph-
eral blood mononuclear cells from healthy young donors were stimu-
lated with phytohemagglutinin and then washed and cultured alone or
with 50 M H2O2 or 50 M ONOO
 added on days 1, 2, and 3. CD4
cells were then isolated and DNA purified, and killer cell
immunoglobulin-like receptor 2DL4 (KIR2DL4) (A) and TNFSF7
(CD70) (B) promoter methylation was measured by bisulfite sequenc-
ing. Results are presented as the average methylation of dC bases in
CG pairs numbered relative to the transcription start site. Bars show
the mean SEM of 4 experiments for KIR2DL4 and 3 experiments for
TNFSF7. P values are versus control for each sequence. ANOVA 
analysis of variance.
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densitometric analyses from 6 independent experiments
comparing the effects of the test reagents on PMA-
stimulated Raf phosphorylation, while Figure 4C shows
the effects on MEK, and Figure 4D shows the effects on
ERK. All 3 reagents decreased ERK pathway signaling,
indicating a common pathway for the effects of hydral-
azine, H2O2, and ONOO
 on CD4 T cell gene expres-
sion.
PKC inactivation. We previously showed that
oxidative damage to PKC contributes to the ERK
pathway signaling defect in lupus T cells (16), and that
hydralazine also inhibits PKC (33). We therefore inves-
tigated if H2O2 and ONOO
 also inactivate T cell
PKC. CD4 T cells were isolated from healthy young
controls, treated with 10 M hydralazine, 50 M H2O2,
or 50 M ONOO for 60 minutes, and then stimulated
with PMA as in Figure 4. Hydralazine, H2O2, and
ONOO all inhibited PKC phosphorylation (Figure 5).
DISCUSSION
T cells are typically activated during the course of
an immune response, and the increased metabolic de-
mands stimulate mitochondrial oxidative phosphoryla-
tion, resulting in ATP generation to provide energy for
the synthetic reactions. However, oxidative phosphory-
lation also generates reactive oxygen intermediates
(ROIs) such as O2
 (8). T cell stimulation also generates
NO which acts as an intracellular signaling molecule (8).
Importantly, NO can combine with O2
 to form
ONOO, which nitrates intracellular molecules, includ-
ing proteins, DNA, and lipids (10). The consequences of
these covalent modifications on CD4 T cell function in
normal immune responses are incompletely understood,
but chronic stimulation and consequent oxidative stress
may result in the death of some T cells through apopto-
sis (34) or necrosis (8) as well as the epigenetic modifi-
cations described above.
The effects of oxidative stress on T cell function
and gene expression appear to be clinically silent in most
people who have ongoing inflammatory immune re-
sponses, but who lack a sufficient number of genes
predisposing to lupus and perhaps other forms of auto-
immunity. In contrast, lupus tends to flare when people
with a sufficiently large total genetic risk for lupus
encounter environmental agents, such as UV light, in-
fections, silica, cigarette smoke, and others, that stimu-
late inflammatory responses (4–6). Evidence for the
oxidative damage comes from reports that serum pro-
Figure 4. Decreased ERK pathway signaling in CD4 T cells treated with H2O2 or ONOO
. CD4 T cells from 6 healthy young donors were
treated with 10 M hydralazine (Hyd), 50 M H2O2, or 50 M ONOO
 for 60 minutes and then stimulated with phorbol myristate acetate (PMA)
for 15 minutes. The cells were then lysed and Raf, MEK, and ERK phosphorylation was measured by immunoblotting. A, Representative
immunoblots of Raf, MEK, and ERK phosphorylation in untreated cells and cells treated with hydralazine, H2O2, or ONOO
. B–D,
Phosphorylation of Raf (B), MEK (C), and ERK (D) in cells treated with hydralazine, H2O2, or ONOO
. Bars show the mean SEM. Values above
the bars are P versus control.
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teins from patients with active lupus have elevated levels
of 3-nitrotyrosine, caused by ONOO reacting with Tyr,
as well as elevated levels of protein-bound carbonyls
relative to healthy controls (9). ONOO can also oxidize
lipids including low-density lipoproteins (LDLs), and
circulating complexes of antiphospholipid antibodies
and oxidized LDLs are found in lupus patients with
antiphospholipid antibody syndrome (35). The inflam-
matory response caused by the autoimmune flare may
also further increase the amount of ROIs generated.
The experiments presented above demonstrate
that treating dividing T cells with H2O2 or ONOO

demethylates T cell DNA by decreasing ERK pathway
signaling, decreasing DNMT-1 expression, and prevent-
ing the replication of DNA methylation patterns during
mitosis, similar to previous results with the PKC inhib-
itor hydralazine (16) as well as with the DNMT-1
inhibitors 5-azacytidine and procainamide, and the
MEK inhibitors PD98059 and U0126. Further, the same
KIR2DL4 sequences demethylate in CD4 T cells from
patients with active but not inactive lupus (19), consis-
tent with our previous reports that the methylation
status of some T cell DNA sequences is less stringently
maintained than others (36–38). Demethylation of reg-
ulatory elements then increases the expression of T cell
genes normally suppressed at least in part by DNA
methylation, including CD70 and KIR (20,22). We also
found that 1 mM (163 mg/liter) NAC, an antioxidant,
prevented these epigenetic effects. This observation
further supports a role for ROIs in gene demethylation
and activation, and suggests that environmental agents
that cause inflammation may stimulate generation of
reactive oxygen species that have similar epigenetic
effects on T lymphocyte gene expression in vivo. This is
clinically relevant because 600 mg of NAC can be safely
administered twice a day for 2 days to prevent contrast-
induced kidney damage (39), and one 600 mg dose gives
a peak blood level of 465 mg/liter (40). This suggests that
NAC may also prevent or treat lupus flares, as proposed
by Lai et al (29).
Importantly, inhibiting T cell PKC activation
and downstream ERK pathway signaling is sufficient to
cause lupus-like autoimmunity in animal models. We
reported that inhibiting CD4 T cell DNA methylation,
either by treatment with direct DNMT-1 inhibitors such
as procainamide and 5-azacytidine, or with ERK path-
way inhibitors such as U0126 or hydralazine, causes
demethylation and overexpression of genes including
CD11a, perforin, CD70, and the KIR gene family (3,20),
and that injecting CD4 T cells treated with either
DNMT-1 inhibitors or ERK pathway inhibitors is suffi-
cient to cause lupus-like autoimmunity in syngeneic
mice (13). Importantly, procainamide and hydralazine
cause drug-induced lupus (3). Further, MEK is a key
signaling molecule in the ERK pathway, and inducing
expression of a dominant negative MEK selectively in T
cells also causes lupus-like autoimmunity in transgenic
mice by decreasing DNMT-1 levels (14,15), indicating
the importance of ERK pathway defects in lupus-like
diseases.
Abnormal ERK pathway signaling in T cells may
similarly contribute to flares in patients with lupus.
Lupus T cells are characterized by multiple intracellular
signaling abnormalities, including decreased ERK path-
way signaling, increased mammalian target of rapamycin
signaling, enhanced Ca2 fluxes, TCR dysregulation,
decreased Elf-1 levels, increased PP2A expression, and
others (41,42). The mechanism(s) causing these abnor-
malities are unclear, and whether the abnormalities are
secondary to the disease process or contribute to disease
flares is unknown. However, since decreased ERK path-
way signaling in T cells causes lupus-like autoimmunity
Figure 5. Protein kinase C (PKC) inactivation in CD4 T cells
treated with hydralazine (Hyd), H2O2, or ONOO
. A, CD4 T cells
from a healthy young donor were cultured with 10 M hydralazine for
60 minutes, stimulated with phorbol myristate acetate (PMA) for 15
minutes, and then lysed, and PKC phosphorylation was measured by
immunoblotting. -actin was used as a loading control. B, CD4 T
cells from a healthy young donor were cultured with 50 M H2O2 and
stimulated with PMA, and PKC phosphorylation was measured by
immunoblotting. C, CD4 T cells from a healthy young donor were
cultured with 50 M ONOO for 60 minutes and stimulated with
PMA for 15 minutes, and PKC phosphorylation was measured by
immunoblotting. D, PKC phosphorylation was quantified in CD4
T cells treated with hydrazaline, H2O2, or ONOO
. Bars show the
mean  SEM from 6 similar experiments for each treatment. P values
are versus control.
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in animal models (14,15), the ERK pathway signaling
defect found in T cells from patients with active lupus
may be causative rather than secondary to the conse-
quences of a lupus flare. The role of oxidative stress in
the other lupus T cell signaling abnormalities is un-
known.
Linking oxidative stress to epigenetic changes
may have direct therapeutic relevance to lupus. First,
avoiding environmental agents that cause oxidative
stress may delay disease onset and prevent flares. Sec-
ond, antioxidants like NAC or others may have thera-
peutic benefit by scavenging the reactive oxygen species
generated during inflammatory responses, possibly pre-
venting flares or decreasing flare severity (29).
In summary, agents causing oxidative stress are
implicated in triggering lupus flares (4–6). The findings
of the present study indicate that the ROIs mediating
oxidative stress can contribute to epigenetic changes in T
cells that resemble those found in patients with active
lupus (3,25,43) and that cause lupus-like autoimmunity
in animal models (14). These studies thus suggest that
environmental agents that cause inflammatory re-
sponses may trigger lupus flares in genetically predis-
posed people through effects on T cell signaling path-
ways, and that antioxidants may help prevent lupus onset
and flares.
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